Navigation Links
Novel therapeutic targets identified for small cell lung cancer
Date:9/6/2012

PHILADELPHIA Newly discovered molecular differences between small cell lung cancer and nonsmall cell lung cancer have revealed PARP1 and EZH2 as potential therapeutic targets for patients with small cell lung cancer, according to the results of a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

Currently, small cell lung cancer accounts for about 15 percent of lung cancer diagnoses in the United States. Patients with the disease will initially respond to chemotherapy, but almost all will have disease recurrence within a couple of months, according to Lauren A. Byers, M.D., assistant professor of thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center in Houston.

"Unlike nonsmall cell lung cancer [NSCLC], where there have been new targeted drugs developed in the last ten years, the only currently approved treatments for small cell lung cancer are cytotoxic chemotherapies," Byers said. "Because most targeted therapies directly act on proteins, identifying if certain proteins are overexpressed in small cell lung cancer could have therapeutic applications."

In order to identify molecular differences between NSCLC and the more aggressive small cell lung cancer, Byers and colleagues used tools called reverse phase protein arrays. These allow the examination of the expression of about 200 proteins that are in key signaling pathways known to be involved in driving cancer growth.

"We discovered that small cell lung cancer and NSCLC have dramatically different protein profiles in terms of which proteins are 'turned on' and are driving the behavior of these cancers," Byers said. "In small cell lung cancer, proteins that were present at higher levels included several DNA repair proteins such as PARP1 and a protein involved in cancer stem cell renewal, EZH2."

PARP1 was further evaluated as a target for treatment of small cell lung cancer because there are several PARP inhibitors in advanced-stage clinical trials for other tumor types such as breast and ovarian cancers. Moreover, small cell lung cancer is sensitive to platinum-based chemotherapy, and PARP inhibitors have shown increased activity when used on other platinum-sensitive tumors.

Two PARP inhibitors were tested on small cell lung cancer cell lines alone and in combination with standard frontline chemotherapeutics, cisplatin and etoposide, or another commonly used chemotherapeutic, irinotecan. The inhibitors slowed the growth of small cell lung cancer cells, but not non-neuroendocrine NSCLC cells, according to the study. In addition, levels of PARP1 expression directly correlated with PARP inhibitor sensitivity.

As with many targeted drugs, it is possible that combining PARP inhibitors with other targeted drugs may significantly improve efficacy, according to Byers.

"Our next step is to begin to examine the use of PARP inhibitors in combination with other drugs in preclinical and clinical investigations of small cell lung cancer," she said.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Novel technique demonstrates interactions between malaria parasite and HIV
2. Genetic analyses reveal novel mutations as causes of startle disease
3. UNC team describes novel inflammatory protein function
4. Study finds novel therapy that may prevent damage to the retina in diabetic eye diseases
5. LA BioMed investigator, Dr. Yutaka Niihara, developing novel cellular therapy
6. New method to find novel connections from gene to gene, drug to drug and between scientists
7. Novel pig model may be useful for human cancer studies
8. Novel anti-malarial drug target identified
9. ICAP study uses novel incentive to encourage HIV patient care and treatment
10. Researchers to use novel metabolomics technology for COPD
11. Cell differentiation as a novel strategy for the treatment of an aggressive type of skin cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2020)... ... March 27, 2020 , ... ... OrthoSC is now offering telemedicine as an alternative approach to seeing their ... practice’s doctors in the comfort of their own home or office using video ...
(Date:3/28/2020)... ... , ... iPatientCare, a pioneer in cloud-based ambulatory EHR ... expanded the availability of telehealth services and other initiatives to help clients amid ... big role in fighting coronavirus . Increasing the telehealth services across the nation ...
(Date:3/27/2020)... ... 27, 2020 , ... Justin P. Kubeck, MD of Ocean ... has been approved every year consecutively since 2016. Dr. Kubeck is board certified ... , Dr. Kubeck’s medical education began at Thomas Jefferson University. He then completed ...
(Date:3/27/2020)... , ... March 27, 2020 , ... ... addressing unmet needs in the field of urology, today announced that Harpreet Wadhwa, ... UroLift® Center of Excellence. The designation recognizes that Dr. Wadhwa has achieved a ...
(Date:3/22/2020)... ... March 21, 2020 , ... The modular construction industry, led ... (MHBA), have been working with state and federal officials on ways to support ... use of modular construction to address the nation’s affordable housing crisis well before ...
Breaking Medicine News(10 mins):
(Date:3/30/2020)... ... March 30, 2020 , ... “In the time ... Unfortunately, we hear stories from our customers of vendor price-gouging. We are here ... of people’s hardships in this difficult time,” says Borya Shakhnovich, CEO of airSlate ...
(Date:3/28/2020)... ... , ... Known for bridging the gap between wellness and beauty through her ... in response to the COVID-19 outbreak. , As hand washing and arm bumping become ... next several months even in the absence of the COVID-19 virus. However, this pandemic has ...
(Date:3/27/2020)... ... ... Why a Podcast for Procap Medical Billing? , One of the main ... to explain more about what her business entails on a regular basis. There are ... the process of claim follow-up, conversing and networking with health care companies, and attaining ...
Breaking Medicine Technology: